Why the study?
Do antiarrhythmic drugs, pharmacologic therapy, and implantable cardioverter defibrillators improve survival in patients post-MI, with CHF, or with sustained ventricular tachyarrhythmias?
Do antiarrhythmic drugs, pharmacologic therapy, and implantable cardioverter defibrillators improve survival in patients post-MI, with CHF, or with sustained ventricular tachyarrhythmias?
This review summarizes a decade of clinical trials on antiarrhythmic therapies and ICDs, providing treatment recommendations for patients with heart failure, post-MI, and ventricular tachyarrhythmias.
Multiple trials using antiarrhythmic drugs, pharmacologic therapy, and implantable cardioverter defibrillators have been performed in an attempt to improve survival in patients: (1) postmyocardial infarction; (2) with congestive heart failure, with and without nonsustained ventricular tachycardia; and (3) with sustained ventricular tachycardia and those who have survived an out-of-hospital cardiac arrest. This article reviews some of the key findings and limitations of completed and ongoing trials. We also make recommendations for the current treatment of such patients based on the results of these trials.
No takes yet. Share an insight, caveat, or question.
NACCARELLLI et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: